Urology · 2026
Benign Prostatic Hyperplasia Pharmacotherapy and Incident Ocular Surface Disease: Comparative Risk of Alpha-Blockers vs 5-Alpha Reductase Inhibitors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ahmed Zaid, Chawareb Elia Abou, Hammad Muhammed A M, Senel Samet, Matar Yara, Miller Jake, Shahait Mohammed, Yafi Faysal A
Аннотация
OBJECTIVE: To compare the risk of incident ocular surface disease (OSD) among men treated with alpha-blockers vs 5-alpha reductase inhibitors (5-ARIs) for benign prostatic hyperplasia (BPH).
METHODS: A retrospective cohort study using data from a de-identified electronic health record database was performed. Adult men diagnosed with BPH taking either an alpha-blocker or a 5-ARI were included, along with untreated BPH controls. OSD was defined using ICD-10-based concept sets for dry eye and related tear-film disorders. Time-to-event analyses were performed using Kaplan-Meier methods and Cox proportional hazards regression adjusting for age, diabetes, autoimmune disease, hypertension, hyperlipidemia, and PDE5i use.
RESULTS: Among 2538 treated men (2303 alpha-blocker; 235 5-ARI), 235 OSD events occurred. Compared with alpha-blockers, 5-ARI use was associated with lower OSD risk in unadjusted (HR 0.47; 95% CI 0.27-0.82; P = .008) and adjusted analyses (HR 0.37; 95% CI 0.19-0.65; P = .001). Kaplan-Meier analysis demonstrated greater OSD-free survival among 5-ARI users (P = .008). In a three-group model including untreated patients, alpha-blocker use was associated with increased OSD risk vs no treatment (HR 3.77; 95% CI 2.34-6.06), while 5-ARI use was not (HR 1.31; 95% CI 0.67-2.82).
CONCLUSION: Alpha-blockers were associated with increased OSD risk relative to untreated patients. Compared with alpha-blockers, 5-ARI use was associated with lower OSD risk and was not significantly different from untreated controls. These findings may inform therapeutic decision-making, particularly in men at risk for OSD.
METHODS: A retrospective cohort study using data from a de-identified electronic health record database was performed. Adult men diagnosed with BPH taking either an alpha-blocker or a 5-ARI were included, along with untreated BPH controls. OSD was defined using ICD-10-based concept sets for dry eye and related tear-film disorders. Time-to-event analyses were performed using Kaplan-Meier methods and Cox proportional hazards regression adjusting for age, diabetes, autoimmune disease, hypertension, hyperlipidemia, and PDE5i use.
RESULTS: Among 2538 treated men (2303 alpha-blocker; 235 5-ARI), 235 OSD events occurred. Compared with alpha-blockers, 5-ARI use was associated with lower OSD risk in unadjusted (HR 0.47; 95% CI 0.27-0.82; P = .008) and adjusted analyses (HR 0.37; 95% CI 0.19-0.65; P = .001). Kaplan-Meier analysis demonstrated greater OSD-free survival among 5-ARI users (P = .008). In a three-group model including untreated patients, alpha-blocker use was associated with increased OSD risk vs no treatment (HR 3.77; 95% CI 2.34-6.06), while 5-ARI use was not (HR 1.31; 95% CI 0.67-2.82).
CONCLUSION: Alpha-blockers were associated with increased OSD risk relative to untreated patients. Compared with alpha-blockers, 5-ARI use was associated with lower OSD risk and was not significantly different from untreated controls. These findings may inform therapeutic decision-making, particularly in men at risk for OSD.